Novartis Acquires Myricx Bio to Advance Next-Generation NMTi Antibody-Drug Conjugate Pipeline

Novartis acquires Myricx Bio to advance next-generation antibody-drug conjugate (ADC) innovation using a novel N-myristoyltransferase inhibitor (NMTi) payload platform. This proposed acquisition strengthens the Novartis oncology pipeline by integrating two lead investigational ADC assets and a broader payload platform designed specifically to address resistance to current therapeutic options, including commonly used topoisomerase-1 (TOPO-1) inhibitors. By targeting solid tumors through a completely differentiated cancer-killing payload mechanism, the agreement underscores a concerted effort to broaden targeted treatment opportunities and expand clinical options for cancer patients worldwide.

The privately held, UK-based biotechnology company, Myricx Bio, has focused its proprietary platform on developing a new class of ADCs. Through this proposed deal, Novartis acquires Myricx Bio to combine the high specificity of monoclonal antibodies with potent cytotoxic payloads to destroy tumor cells selectively while minimizing exposure to healthy tissues. Myricx’s two lead clinical assets are directed toward the high-value cancer targets B7-H3 and HER2, both of which possess significant therapeutic potential across a wide variety of solid tumor settings.

According to leadership at Novartis, expanding innovative platforms is a cornerstone of their long-term therapeutic vision. As Novartis acquires Myricx Bio, Fiona Marshall, President of Biomedical Research at Novartis, highlighted that while ADCs have cemented their role as an essential component of modern cancer treatment, there remains a critical clinical need for entirely new payload mechanisms to overcome drug resistance. Marshall stated that Myricx Bio’s promising NMTi payload platform features a highly differentiated mechanism that could successfully expand the utility of ADCs across multiple solid tumor settings, mirroring how the company previously scaled its radioligand therapies.

Under the definitive terms established in the acquisition agreement, Novartis acquires Myricx Bio for an upfront payment of USD 1.1 billion. Furthermore, the contract outlines provisions for up to USD 400 million in potential additional milestone payments, which are directly tied to development progress and clinical validation. According to the official Novartis Press Release, the multi-billion-dollar transaction remains subject to customary closing conditions, including necessary regulatory approvals, and is fully expected to close in the second half of 2026.

Learn More

Novartis Ianalumab Clinches FDA Breakthrough Status, Aiming to Be First Targeted Treatment for Sjögren’s Disease

The underlying biological mechanism of the acquired platform centers on the inhibition of N-myristoyltransferase (NMT). NMT is an enzyme responsible for enabling critical proteins to function properly inside cells, a process that cancer cells depend heavily upon to survive, proliferate, and grow. Because this agreement marks a landmark shift as Novartis acquires Myricx Bio, researchers aim to leverage this unique NMTi payload to disrupt these vital processes directly within tumor cells. Preclinical data strongly suggest that the NMTi payload maintains robust anti-tumor activity across multiple solid tumors, including advanced models that have already developed resistance to conventional TOPO-1 inhibitor-based ADCs.

Beyond immediate pipeline additions, the acquisition provides Novartis with an expansive opportunity to help pioneer NMTi as an entirely new, clinically validated class of ADC payloads. If clinical validation supports its efficacy, safety, and therapeutic index, the NMTi payload platform could eventually be combined with additional tumor-associated targets and alternative delivery platforms. This opens up entirely new design spaces for future conjugate development, moving beyond incremental modifications of existing therapies to deliver truly transformative clinical outcomes via biomedical research initiatives.

Transaction and Financial Overview

Clinical Pipeline Assets & Technical Mechanism Data

Component / Asset	Target Interaction / Target Antigen	Intended Therapeutic Application	Clinical Performance & Background
NMTi Payload Platform	N-myristoyltransferase (NMT) Enzyme Inhibition	Broad-spectrum Solid Tumors	Potential first-in-class platform; disrupts processes vital for cancer cell survival; overcomes TOPO-1 resistant models in preclinical testing.
Lead Investigational Asset 1	B7-H3 Antigen	Multiple Solid Tumor Settings	Designed to deliver a differentiated cancer-killing payload directly to tumor cells.
Lead Investigational Asset 2	HER2 Receptor	Multiple Solid Tumor Settings	Targeted drug conjugate using the novel NMTi platform mechanism.

Learn More

Novartis Achieves Phase III Remibrutinib Trial Primary Endpoint in Chronic Inducible Urticaria